{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:54:45Z","timestamp":1789419285738,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016259","name":"Mylan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.semarthrit.2022.152023","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T02:14:40Z","timestamp":1651889680000},"page":"152023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152023_bib0001","unstructured":"U.S. Food and Drug Administration. Biosimilar development, review, and approval. October 20, 2017. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval (accessed September 11, 2020)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0002","unstructured":"European Medicines Agency. Biosimilar medicines: overview. October 29, 2019. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview (accessed September 23, 2020)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0003","unstructured":"Healio. FDA approves Hulio, sixth Humira biosimilar. July 9, 2020. https:\/\/www.healio.com\/news\/rheumatology\/20200709\/fda-approves-hulio-sixth-humira-biosimilar (accessed September 14, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0004","unstructured":"U.S. Food and Drug Administration. Biosimilar Product Information. July 29, 2021. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information (accessed September 15, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0005","unstructured":"Ray F. Nepexto, Enbrel biosimilar, approved to treat patients in Europe. June 15, 2020. https:\/\/ankylosingspondylitisnews.com\/2020\/06\/15\/nepexto-enbrel-biosimilar-approved-eu-treat-ankylosing-spondylitis-other-inflammatory-disorders\/ (accessed September 23, 2020)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0006","unstructured":"National Psoriasis Foundation. Biologics. https:\/\/www.psoriasis.org\/biologics\/ (accessed September 15, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0007","unstructured":"Biosimilars Hotspots Infographic Q2 2021, Emerging Biosimilars, Clarivate. https:\/\/clarivate.com\/cortellis\/wp-content\/uploads\/sites\/4\/2020\/11\/Evolving-Biosimilars-Landscape_On-Demand-Webinar_final_20Oct2020.pdf (accessed September 19, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0008","article-title":"Specialty pharmacy by the numbers","author":"Pahlavan","year":"2019","journal-title":"Pharm Times"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152023_bib0009","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nbt1030","article-title":"Characterizing biological products and assessing comparability following manufacturing changes","volume":"22","author":"Chirino","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0010","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2147\/DDDT.S130318","article-title":"Ten years of biosimilars in Europe: development and evolution of the regulatory pathways","volume":"11","author":"Schiestl","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0011","unstructured":"Medicines for Europe. Oncology,the new era for biosimilar medicines September 8, 2017. https:\/\/www.medicinesforeurope.com\/news\/oncology-the-new-era-for-biosimilar-medicines\/ (accessed September 14, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0012","unstructured":"European Medicines Agency and the European Commission. Biosimilars in the EU: information guide for healthcare professionals. October 2019. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (accessed March 17, 2020)."},{"issue":"19","key":"10.1016\/j.semarthrit.2022.152023_bib0013","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.2020.2229","article-title":"Coverage for biosimilars vs reference products among US commercial health plans","volume":"323","author":"Chambers","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152023_bib0014","doi-asserted-by":"crossref","first-page":"E668","DOI":"10.1001\/amajethics.2019.668","article-title":"Why are biosimilars not living up to their promise in the US?","volume":"21","author":"Zhai","year":"2019","journal-title":"AMA J Ethics"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0015","article-title":"Biosimilars: patient perspectives, challenges and emerging solutions: current opinions","volume":"5","author":"Frapaise","year":"2019","journal-title":"J Drug Res Dev"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152023_bib0016","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/art.41201","article-title":"Utilization and treatment costs of tumor necrosis factor inhibitors after the introduction of biosimilar infliximab in the United States","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0017","unstructured":"European Commission. Defining value in 'value-based healthcare.' Report of the Expert Panel on Effective Ways of Investing in Health (EXPH). Published July 19, 2019. https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/beaebce1-ac29-11e9-9d01-01aa75ed71a1\/language-en (accessed September 28, 2021)."},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152023_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jval.2019.12.003","article-title":"Economic evaluation of sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to methotrexate in France","volume":"23","author":"Ghabri","year":"2020","journal-title":"Value Health"},{"issue":"suppl 2","key":"10.1016\/j.semarthrit.2022.152023_bib0019","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/annrheumdis-2017-eular.3380","article-title":"THU0656 Etanercept biosimilar usage and associated cost savings in Germany","volume":"76","author":"Thakur","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0020","unstructured":"World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). October 19\u201323, 2009. http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed August 3, 2021)."},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0021","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13075-019-1857-3","article-title":"An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis","volume":"21","author":"Cohen","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152023_bib0022","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/14712598.2019.1645114","article-title":"Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)","volume":"19","author":"Cohen","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152023_bib0023","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/13543784.2020.1723000","article-title":"A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA\u00ae) with the reference product (Humira\u00ae) in healthy volunteers","volume":"29","author":"Jamshidi","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13075-020-02394-7","article-title":"Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study","volume":"23","author":"Kay","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152023_bib0025","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/1756-185X.13951","article-title":"Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis","volume":"23","author":"Alten","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152023_bib0026","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","article-title":"Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study","volume":"34","author":"Wiland","year":"2020","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10067-020-05199-w","article-title":"Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases","volume":"40","author":"Bruni","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152023_bib0028","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.40444","article-title":"Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0029","doi-asserted-by":"crossref","first-page":"14270","DOI":"10.1038\/s41598-020-64991-5","article-title":"Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: a controlled, randomized and multicenter study","volume":"10","author":"Wu","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00228-020-02957-2","article-title":"Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center","volume":"77","author":"Al Tabaa","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152023_bib0031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5114\/reum.2019.89516","article-title":"Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar","volume":"57","author":"Felis-Giemza","year":"2019","journal-title":"Reumatologia"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152023_bib0032","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/annrheumdis-2019-216702","article-title":"Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries","volume":"79","author":"Glintborg","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152023_bib0033","doi-asserted-by":"crossref","first-page":"365","DOI":"10.55563\/clinexprheumatol\/usrd9z","article-title":"BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis","volume":"39","author":"Selmi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152023_bib0034","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.40516","article-title":"Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152023_bib0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s13318-020-00613-9","article-title":"An open-label, randomized, single-dose, crossover, comparative pharmacokinetics study of YLB113 and the etanercept reference product in healthy adult male subjects","volume":"45","author":"Shennak","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0036","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40744-019-00186-3","article-title":"A comparative study to assess the efficacy, safety, and immunogenicity of YLB113 and the etanercept reference product for the treatment of patients with rheumatoid arthritis","volume":"7","author":"Yamanaka","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152023_bib0037","doi-asserted-by":"crossref","first-page":"753","DOI":"10.55563\/clinexprheumatol\/pa6lap","article-title":"Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons","volume":"39","author":"Convertino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"10086","key":"10.1016\/j.semarthrit.2022.152023_bib0038","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152023_bib0039","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40261-020-00907-5","article-title":"A 5-year retrospective analysis of drug survival, safety, and effectiveness of the infliximab biosimilar CT-P13 in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"Kim","year":"2020","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152023_bib0040","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152023_bib0041","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40259-019-00403-z","volume":"34","author":"Cohen","year":"2020","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152023_bib0042","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/1756-185X.13846","article-title":"A comparative study of PF-06438179\/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: a subgroup analysis","volume":"23","author":"Kameda","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152023_bib0043","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/cpdd.845","article-title":"A randomized, double-blind study comparing pharmacokinetics and pharmacodynamics of proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate to severe rheumatoid arthritis","volume":"9","author":"Burmester","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152023_bib0044","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s10067-020-05305-y","article-title":"Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis","volume":"39","author":"Burmester","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152023_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40259-020-00406-1","article-title":"Pharmacokinetic similarity and comparative pharmacodynamics, safety, efficacy, and immunogenicity of DRL_RI versus reference rituximab in biologics-na\u00efve patients with moderate-to-severe rheumatoid arthritis: a double-blind, randomized, three-arm study","volume":"34","author":"Haridas","year":"2020","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0046","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/rheumatology\/keaa234","article-title":"Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial","volume":"60","author":"Smolen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152023_bib0047","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0048","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14712598.2021.1851362","article-title":"Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study","volume":"21","author":"Menter","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0049","article-title":"VOLTAIRE-X phase III data in patients with moderate-to-severe chronic plaque psoriasis support interchangeability application. News release","year":"2021","journal-title":"Boehringer Ingelheim"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152023_bib0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaad.2019.12.071","article-title":"Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: an open-labeled, prospective, pilot case series","volume":"83","author":"Khandpur","year":"2020","journal-title":"J AmAcad Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152023_bib0051","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"The Br J Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152023_bib0052","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjd.18220","article-title":"AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"182","author":"Hercogov\u00e1","year":"2020","journal-title":"BrJ Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152023_bib0053","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/dth.13435","article-title":"SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis","volume":"33","author":"Di Cesare","year":"2020","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152023_bib0054","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/09546634.2019.1606886","article-title":"Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study","volume":"31","author":"Bonifati","year":"2020","journal-title":"JDermatolog Treatment"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152023_bib0055","first-page":"316","article-title":"Real world SB4 (etanercept biosimilar) use in patients with psoriasis: data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"19","author":"Egeberg","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0056","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211031420","article-title":"A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study","volume":"14","author":"Barberio","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152023_bib0057","first-page":"195","article-title":"Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study","volume":"112","author":"Ribaldone","year":"2020","journal-title":"Rev Esp Enferm Dig"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152023_bib0058","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2468-1253(21)00252-1","article-title":"Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial","volume":"6","author":"Hanauer","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0059","first-page":"191","article-title":"Efficacy and safety of adalimumab biosimilar (Exemptia) in moderate-to-severe steroid-refractory ulcerative colitis patients: real-life outcomes in resource-constrained setting at 24-weeks follow-up","volume":"13","author":"Chandra","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab100","article-title":"Effectiveness and safety of adalimumab biosimilar SB5 in IBD: outcomes in originator to SB5 switch, double biosimilar switch and bio-naieve SB5 observational cohorts","author":"Derikx","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152023_bib0061","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/ecco-jcc\/jjaa001","article-title":"Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre","volume":"14","author":"Lukas","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"15","key":"10.1016\/j.semarthrit.2022.152023_bib0062","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10153387","article-title":"Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn's disease: a prospective study","volume":"10","author":"Ribaldone","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152023_bib0063","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/apa.15026","article-title":"Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease","volume":"109","author":"Nikkonen","year":"2020","journal-title":"Acta Paediatr"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152023_bib0064","doi-asserted-by":"crossref","first-page":"e00177","DOI":"10.14309\/ctg.0000000000000177","article-title":"Infliximab originator, infliximab biosimilar, and adalimumab are more effective in Crohn's disease than ulcerative colitis: a real-life cohort study","volume":"11","author":"Barberio","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0065","article-title":"Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study","author":"Hanzel","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152023_bib0066","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.cgh.2018.12.036","article-title":"Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to Remicade","volume":"17","author":"Ilias","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152023_bib0067","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7326\/M18-1512","article-title":"Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study","volume":"170","author":"Meyer","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152023_bib0068","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00384-020-03703-x","article-title":"Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis","volume":"35","author":"Ollech","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152023_bib0069","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.clinre.2019.11.008","article-title":"Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: a12-month prospective observational cohort study","volume":"44","author":"Petitdidier","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152023_bib0070","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"10182","key":"10.1016\/j.semarthrit.2022.152023_bib0071","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152023_bib0072","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.dld.2019.09.020","article-title":"Anti-TNF dose escalation and drug sustainability in Crohn's disease: data from the nationwide administrative database in Hungary","volume":"52","author":"K\u00f3sa","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152023_bib0073","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ibd\/izaa036","article-title":"The SPOSIB SB2 Sicilian Cohort: safety and effectiveness of infliximab biosimilar SB2 in inflammatory bowel diseases, including multiple switches","volume":"27","author":"Macaluso","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0074","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211023384","article-title":"Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study","volume":"14","author":"Massimi","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152023_bib0075","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152023_bib0076","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0077","unstructured":"Harston A.H. U.S. biosimilar launches accelerate with five launches in Q4 2019 and early 2020. January 28, 2020. https:\/\/www.biosimilarsip.com\/2020\/01\/28\/u-s-biosimilar-launches-accelerate-with-five-launches-in-q4-2019-and-early-2020\/ (accessed September 23, 2020)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0078","unstructured":"U.S. Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018. https:\/\/www.fda.gov\/media\/114574\/download (accessed September 23, 2020)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0079","unstructured":"CNBC News Release. CNBC Exclusive: cNBC's Meg Tirrell interviews FDA 70 Scott Gottlieb from CNBC's Health Returns Conference today. March 28, 2018. https:\/\/www.cnbc.com\/2018\/03\/28\/cnbc-exclusive-cnbcs-meg-tirrell-interviews-fda-commissioner-scott-gottlieb-from-cnbcs-healthy-returns-conference-today.html (accessed September 15, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0080","unstructured":"European Medicines Agency. Medicines. https:\/\/www.ema.europa.eu\/en\/medicines\/search_api_aggregation_ema_medicine_types\/field_ema_med_biosimilar\/ema_group_types\/ema_medicine (accessed February 10, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0081","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. October 23, 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf (accessed September 23, 2020)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.09.006","article-title":"Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial","author":"Bielsky","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0083","unstructured":"Agency MHpR. Guidance on the licensing of biosimilar products. May 6, 2021. https:\/\/www.gov.uk\/government\/publications\/guidance-on-the-licensing-of-biosimilar-products\/guidance-on-the-licensing-of-biosimilar-products (accessed August 6, 2021)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0084","first-page":"1","article-title":"Olry de Labry A. The impact of biosimilars\u2019 entry in the EU market","volume":"30","author":"Rovira","year":"2011","journal-title":"Andal Sch Public Health"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0085","unstructured":"European Generic Medicines Association. EGA handbook on biosimilar medicines. www.bogin.nl\/files\/ega_biosmilarshandbook.pdf (accessed September 23, 2020). [link without http:\/\/worked on 2\/2\/2022]."},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152023_bib0086","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10269-011-2015-y","article-title":"What does a prescriber think of biosimilars?","volume":"13","author":"Aapro","year":"2011","journal-title":"Oncologie"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152023_bib0087","first-page":"2925","article-title":"Clinical experience with Zarzio\u00ae in Europe: what have we learned?","volume":"21","author":"Gasc\u00f3n","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0088","unstructured":"Medicines, Diagnostics and Personalised Medicine Policy Team, National Medical Directorate, NHS England. Commissioning framework for biological medicines (including biosimilar medicines). 2017. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/09\/biosimilar-medicines-commissioning-framework.pdf (accessed September 23, 2020)."},{"key":"10.1016\/j.semarthrit.2022.152023_bib0089","article-title":"After biosmilar deals, UK spending on adalimumab will drop by 75%","author":"Davio","year":"2018","journal-title":"AJMC. The Center for Biosimilars"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152023_bib0090","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","article-title":"Non-pharmacological effects in switching medication: the Nocebo effect in switching from originator to biosimilar agent","volume":"32","author":"Kristensen","year":"2018","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152023_bib0091","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.15223","article-title":"Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients","volume":"49","author":"Pouillon","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152023_bib0092","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5639\/gabij.2014.0302.018","article-title":"Biosimilars naming, label transparency and authority of choice: survey findings among European physicians","volume":"3","author":"Dolinar","year":"2014","journal-title":"GaBi J"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152023_bib0093","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jbspin.2019.01.001","article-title":"Patients' information and perspectives on biosimilars in rheumatology: a French nation-wide survey","volume":"86","author":"Frantzen","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0094","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2147\/PPA.S104891","article-title":"Patient attitudes and understanding about biosimilars: an international cross-sectional survey","volume":"10","author":"Jacobs","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0095","unstructured":"Biosimilar drugs: learn about the Biosimilars Initiative, the drugs affected and the process to switch from biologic to biosimilar drugs. alberta.ca\/biosimilar-drugs.aspx (accessed September 3, 2020)."},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152023_bib0096","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.3390\/ijerph17114113","article-title":"Physician-level cost control measures and regional variation of biosimilar utilization in Germany","volume":"17","author":"Blankart","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.semarthrit.2022.152023_bib0097","unstructured":"GlobalData Healthcare. Driven by new therapies, the Crohn's disease market will experience significant growth during the next decade. October 9, 2020. https:\/\/www.pharmaceutical-technology.com\/comment\/chrohns-disease-market-growth\/ (accessed February 10, 2021)."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:10:22Z","timestamp":1758733822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":97,"alternative-id":["S0049017222000749"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152023","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152023"}}